Sigyn CardioDialysis™ is a first-in-industry medical device to treat cardiovascular disease, the leading cause of global deaths. Sigyn CardioDialysis™ aims to reduce the circulating presence of inflammatory molecules that fuel cardiovascular disease progression while simultaneously lowing levels of cholesterol transporting lipoproteins that contribute to heart attacks, strokes, and other Major Adverse Cardiovascular Events (MACE). The extracorporeal removal of lipoprotein(a) [Lp(a)] and low-density lipoprotein cholesterol [LDL-C] from the bloodstream (commercially known as lipoprotein apheresis) has been proven to significantly reduce MACE, the primary clinical endpoint to evaluate cardiovascular disease therapies. The annual market for MACE-reducing therapies is estimated to exceed $150 billion.